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Objective: MAPT mutations typically cause behavioral variant frontotemporal
dementia with or without parkinsonism. Previous studies have shown that
symptomatic MAPT mutation carriers have frontotemporal atrophy, yet studies
have shown mixed results as to whether presymptomatic carriers have low gray
matter volumes. To elucidate whether presymptomatic carriers have lower
structural brain volumes within regions atrophied during the symptomatic
phase, we studied a large cohort of MAPT mutation carriers using a voxelwise
approach. Methods: We studied 22 symptomatic carriers (age 54.7  9.1, 13
female) and 43 presymptomatic carriers (age 39.2  10.4, 21 female). Symp-
tomatic carriers’ clinical syndromes included: behavioral variant frontotemporal
dementia (18), an amnestic dementia syndrome (2), Parkinson’s disease (1),
and mild cognitive impairment (1). We performed voxel-based morphometry
on T1 images and assessed brain volumetrics by clinical subgroup, age, and
mutation subtype. Results: Symptomatic carriers showed gray matter atrophy
in bilateral frontotemporal cortex, insula, and striatum, and white matter atro-
phy in bilateral corpus callosum and uncinate fasciculus. Approximately 20% of
presymptomatic carriers had low gray matter volumes in bilateral hippocampus,
amygdala, and lateral temporal cortex. Within these regions, low gray matter
volumes emerged in a subset of presymptomatic carriers as early as their thir-
ties. Low white matter volumes arose infrequently among presymptomatic car-
riers. Interpretation: A subset of presymptomatic MAPT mutation carriers
showed low volumes in mesial temporal lobe, the region ubiquitously atrophied
in all symptomatic carriers. With each decade of age, an increasing percentage
of presymptomatic carriers showed low mesial temporal volume, suggestive of
early neurodegeneration.
Introduction
Mutations in the microtubule-associated protein tau
(MAPT) cause behavioral variant frontotemporal demen-
tia (bvFTD) with or without parkinsonism, with some
patients meeting criteria for progressive supranuclear
palsy (PSP) or corticobasal syndrome.1 As in sporadic
bvFTD, in bvFTD due to MAPT mutations (bvFTD-
MAPT), patients show degeneration in the anterior cingu-
late cortex, insula, striatum, and the amygdala.2,3 In con-
trast to sporadic bvFTD, however, bvFTD-MAPT more
prominently targets the mesial temporal lobe and in par-
ticular, the hippocampus, a region less typically atrophied
in sporadic bvFTD.2,3
Less is known about the timing of brain volume
changes during the presymptomatic phase. Early studies
with small samples suggested that presymptomatic MAPT
mutation carriers did not have apparent gray or white
matter volume differences compared to controls.4,5 Stud-
ies with larger samples, however, have shown mixed
results. A study of 26 symptomatic and presymptomatic
MAPT mutation carriers revealed gray matter trajectories
that suggested that low hippocampus and amygdala vol-
umes arise years before expected symptom onset.6 A dif-
fusion tensor imaging study of 30 presymptomatic MAPT
mutation carriers found early loss of white matter integ-
rity.7 In contrast, a study of 23 presymptomatic MAPT
mutation carriers did not show significantly low gray
matter volumes, although there was a trend toward small
regions of low gray matter volume in mesial temporal
lobes.8
Most previous studies of presymptomatic MAPT muta-
tion carriers have reported only group comparisons whose
limitation is that they do not account for individual
anatomical variation, which could account for mixed
results across studies. To address this gap, we studied a
multisite cohort of 65 MAPT mutation carriers (22 symp-
tomatic and 43 presymptomatic) by analyzing structural
MRI scans with a voxelwise method that detects gray and
white matter differences in individual carriers. We
hypothesized that: 1) regions of low gray or white matter
volume in presymptomatic MAPT mutation carriers
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would resemble atrophy patterns seen in symptomatic
carriers, and 2) a subset of the presymptomatic carriers,
that is, those presumably closer to symptom onset, would
harbor low gray and white matter volumes beyond
expected of their age. Previous literature suggests that
specific MAPT mutations manifest different clinical syn-
dromes;1 therefore, we also explored whether different




Study participants were recruited from: the Memory and
Aging Center at the University of California, San Fran-
cisco (UCSF); Erasmus University Rotterdam; and two
multisite genetic FTD research projects, the Advancing
Research and Treatment for Frontotemporal Lobar
Degeneration (ARTFL) and Longitudinal Evaluation of
Familial Frontotemporal Dementia Subjects (LEFFTDS)
(Table S1). Clinical diagnoses were rendered by the
respective study sites.9
We studied 22 symptomatic MAPT mutation carriers,
43 presymptomatic MAPT mutation carriers and 107
healthy controls, comprised of 91 noncarrier genetic fron-
totemporal lobar degeneration family members and 16
unrelated controls (Table 1). These unrelated controls
were added to the noncarrier family members to create
an even distribution of ages that was similar to the age
range of the MAPT mutation carrier cohorts. Among the
22 symptomatic carriers, 18 had a clinical diagnosis of
bvFTD. Of the 18 with bvFTD, six carried secondary
diagnoses, including PSP syndrome (4); parkinsonism (1);
and depression (1). Of the four remaining symptomatic
carriers: two had an amnestic dementia syndrome, one of
which also had mild behavioral symptoms; one had
Parkinson’s disease (PD) with behavioral symptoms not
meeting bvFTD criteria; and one had mild cognitive
impairment with behavior and language symptoms. All
symptomatic carriers were recruited from UCSF, ARTFL,
or LEFFTDS (Erasmus University did not recruit symp-
tomatic patients).
Presymptomatic carriers were diagnosed as clinically
normal by each respective study site. These participants
were required to have a Mini-Mental State Examination
(MMSE) score ≥ 27, and if the participant did not have
an MMSE score available, participants had a Montreal
Cognitive Assessment (MoCA)10 score ≥ 21. We chose
this threshold for the MoCA score because in participants
tested with both measures, an MMSE score of 27 corre-
sponds to a MoCA score of 21.11 We included three
presymptomatic carriers with a Clinical Dementia Rating
Scale (CDR) plus Behavioral and Language Domains
from the National Alzheimer’s Coordinating Center
(NACC) FTLD module (CDR plus NACC FTLD)12 glo-
bal score of 0.5, as this score may not necessarily be
indicative of incipient phenoconversion to disease. Never-
theless, we repeated each analysis without the three
presymptomatic carriers who had a CDR plus NACC
FTLD global score of 0.5.
Healthy controls were also required to have a MMSE
score ≥ 27 or a MoCA score ≥ 21, a CDR plus NACC
FTLD global score of 0, and no significant history of neu-
rological disease. All participants in the study were
required to have a MRI brain scan free of structural
lesions and prominent white matter disease.
Participants underwent neuropsychological tests at each
site.4,13,14 The CDR plus NACC FTLD scale was avail-
able for the UCSF and ARTFL/LEFFTDS cohorts. Neu-
ropsychological tests were administered within 90 days of
a participant’s MRI scan. We calculated z-scores for each
measure for each participant based on scores of the
healthy controls. For variables with skewed distributions,
we reflected and log transformed the data to improve the
normality of the distribution prior to fitting multiple
regression models. Because these z-scores were not
adjusted for demographic characteristics, we compared
Table 1. Demographics of presymptomatic and symptomatic MAPT mutation carriers.
Presymptomatic Symptomatic Healthy Controls
n 43 22 107
Age at MRI scan, years 39.2 (10.4) 54.7 (9.1) 48.9 (13.2)
M:F, n 22:21 9:13 51:56
Education, years 16.1 (2.4) 15.1 (2.4) 15.9 (2.3)
Education, Dutch 7-point scale1 4.8 (1.7) n/a 5.3 (1.1)
Age at symptom onset n/a 45.6 (8.3) n/a
CDR plus NACC FTLD, global score (0-3) 0.05 (0.15) 1.75 (0.98) 0 (0)
CDR plus NACC FTLD, sum of boxes (max = 24) 0.07 (0.22) 9.73 (6.13) 0 (0)
Unless otherwise indicated, mean values are reported followed by the standard deviation in parentheses.
1Erasmus participants were categorized into levels from 1 = less than 6 years of education to 7 = completed a university degree.
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the z-scores of these cognitive measures for the presymp-
tomatic, symptomatic, and control groups using multiple
regression with age, education, and sex as covariates of
no interest. We compared each MAPT mutation carrier
group to controls using post hoc group-wise compar-
isons.
The Institutional Review Boards at each site approved
this study, and participants or their surrogates provided
informed consent to participate.
Genetic analysis
Participants were screened for pathogenic MAPT muta-
tions.15 All MAPT mutation carriers in the study also
tested negative for GRN mutations and for the C9orf72
repeat expansion.
Image acquisition and preprocessing
Each participant underwent a T1-weighted structural MRI
scan on a 3T scanner. Participants from UCSF were
scanned on a Siemens Tim Trio or a Siemens Prisma
scanner (Table S1). All T1-weighted images were prepro-
cessed with SPM12 (https://www.fil.ion.ucl.ac.uk/spm/).
T1-weighted images were preprocessed using standard
spatial normalization in the SPM12 segment module,
using the six standard tissue probability maps with a light
clean up. Standard affine regularization with the Interna-
tional Consortium for Brain Mapping European brain
template and warping regularization with the default
parameters were used. Images were then segmented into
gray and white matter images, which were smoothed
using an 8-mm full width at half maximum isotropic
Gaussian kernel.
Gray and white matter w-score maps
For each MAPT mutation carrier, we created gray matter
and white matter w-score maps (w-maps) which represent
the difference between the participant’s actual gray or
white matter values in each voxel and the expected value
based on a group of healthy controls.16 A map of w-
scores can be conceptualized as a z-score map of the gray
or white matter residuals after adjustment for covariates
of no interest via regression. To calculate a w-score, vox-
elwise linear regressions were performed on healthy con-
trol gray and white matter maps to determine the
standard deviation of the residuals. Next, the w-score for
each individual participant was calculated voxelwise using
the following formula: w = [(participant’s value – value
predicted for participant age)/SD of residuals of the
healthy control group]. Covariates of no interest included
age, sex, total intracranial volume, site, scanner model,
and scan acquisition protocol. Since the w-score control
group is utilized to build a reference range for brain vol-
ume, we selected controls to cover the age distribution of
the mutation carriers. We prioritized selecting 91 available
mutation-negative family members for our control group
and also included 16 unrelated healthy controls because
of the importance of an even age distribution in our
models.
Gray and white matter relationships with age or
symptom severity
We created group mean w-maps for 1) presymptomatic
and 2) symptomatic carriers by averaging participants’ w-
scores voxelwise and thresholded the maps at w≤-2.16,17
To create frequency gray and white matter w-maps, we
determined the percentage of participants with gray or
white matter values of w≤-2 voxelwise. For presymp-
tomatic carriers, we created group frequency w-maps
binned by age (in decades) to visualize gray and white
matter relationships with age. For symptomatic carriers,
group frequency w-maps were binned by symptom sever-
ity, defined by the CDR plus NACC FTLD global score.
Hemispheric symmetry analysis
Previous studies suggest bilateral and symmetric involve-
ment in symptomatic MAPT mutation carriers.2,3,6 To
determine whether atrophy or low brain volume in symp-
tomatic and presymptomatic MAPT mutation carriers is
symmetric at an individual-subject level, we calculated the
difference between each participant’s mean left and right
hemisphere w-scores for gray or white matter.
Correlations between memory measures and
hippocampal volume
We performed two analyses to explore associations
between memory measures and the volume of the hip-
pocampus, selected as an a priori region because of its
importance in memory recall. First, we calculated for each
participant the mean gray matter w-scores for the left and
right hippocampi (defined by the Automated Anatomical
Labeling atlas18). Verbal memory z-scores were based on
either the California Verbal Learning Test II (CVLT-II)
10 minute delayed recall (UCSF; ARTFL/LEFFTDS) or
the Rey Auditory Verbal Learning Test delayed recall tri-
als (Erasmus). Spatial memory z-scores were based on the
Benson figure recall (UCSF; ARTFL/LEFFTDS). We per-
formed Spearman’s correlations between participants’ hip-
pocampal w-scores and memory z-scores. Second, we
selected the voxel most frequently showing reduced gray
matter across all carriers and created a 4-mm sphere
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around that voxel (and its contralateral homolog) to
determine whether gray matter volume in this MAPT-tar-
geted region correlates with verbal and visual memory
measures. For these analyses, we correlated left hippocam-
pus w-scores with verbal memory scores and right hip-
pocampus w-scores with spatial memory z-scores given
the importance of the left hippocampus for verbal mem-
ory19 and the right hippocampus for spatial memory.20
Next, we searched voxelwise to identify brain regions
where lower memory performance was associated with
lower gray matter volume by correlating verbal then spa-
tial memory z-scores with gray matter w-maps thresh-
olded at P < 0.05 corrected for family-wise error.
The above correlations were performed in all carriers
combined, symptomatic carriers, and presymptomatic
carriers.
MAPT mutation subgroup analysis
Our cohort consisted of participants carrying 13 different
MAPT mutations. Because some mutations had low num-
bers of participants, we examined MAPT mutation sub-
types categorized into five groups by either clinical
(bvFTD-type; amnestic-type; PSP/PD-type) or neu-
ropathological (four repeat-type (4R); and Pick bodies
type) similarity to explore whether different types of
MAPT mutations may target distinct neuroanatomy. The
bvFTD group was comprised of carriers with the V337M
mutation, a missense mutation located on exon 12 which
typically causes bvFTD.21 The amnestic-type group con-
sisted of carriers with R406W, a missense mutation on
exon 13 which typically manifests with an amnestic syn-
drome reminiscent of an Alzheimer’s-like syndrome
rather than a bvFTD syndrome.22,23 The PSP/PD-type
group consisted of carriers with mutations in N279K,
S305N, and S305S, all exon 10 missense mutations which
increase the ratio of 4R to three repeat (3R) tau; these
mutations most often cause bvFTD with PSP or parkin-
sonism.24–28 The 4R-type group consisted of P301L,
S305I, IVS10 + 16C>T, and IVS9-10G> T, a combination
of exonic and splicing mutations which typically present
with bvFTD; these mutations increase exon 10 transcrip-
tion, which increases the ratio of 4R to 3R tau.15,29,30 The
fifth group was the Pick bodies type group which con-
tained G389R, G272V, S320F, and L315R mutations, all
characterized by the inclusion of Pick body or Pick body-
like pathology.31–34 Each group consisted of fewer than 10
symptomatic and presymptomatic carriers combined, with
the exception of the 4R-type group, which had 31 carri-
ers. To protect participant anonymity, we chose not to
report the specific number within each group. We created
mean w-maps for these five mutation subgroups to assess
whether different mutation subtypes target distinct
anatomical regions. Due to the limited number of partici-
pants in each mutation subgroup, we assessed gray and
white matter volume using mean w-maps instead of fre-
quency w-maps.
Results
A subset of presymptomatic carriers harbors
low mesial temporal lobe volumes
In total, the presymptomatic and symptomatic cohorts
included 13 different MAPT mutation subtypes. For most
neuropsychological measures, presymptomatic MAPT
mutation carriers had no statistically significant differ-
ences compared to controls (Tables 2 and 3). The one
exception was that presymptomatic carriers had a signifi-
cantly lower but clinically negligible z-score of 0.39 on
the Multilingual Naming Test (Table 2). With the three
presymptomatic carriers with CDR plus NACC FTLD
global score of 0.5 excluded, results were similar with
presymptomatic carriers largely showing no differences
across measures, with the exception of the Multilingual
Naming Test (z = 0.39, range 1.68, 0.38). Symp-
tomatic carriers showed clinically significant impairments
in verbal learning and memory as well as naming and
semantic verbal fluency, and borderline to low average
performance on most other measures, including attention,
executive functioning, and visual recall, while Benson Fig-
ure Copy was relatively preserved (Table 2).
We found that symptomatic MAPT mutation carriers
had severe bilateral mesial temporal atrophy as well as
frontotemporal and insula atrophy and white matter
involvement in the uncinate fasciculus, anterior corona
radiata, corpus callosum, and inferior longitudinal fasci-
culus (Fig. 1; Fig. S1). Frequency w-maps revealed that
each symptomatic carrier harbored prominent mesial
temporal lobe atrophy and about sixty percent had
involvement within frontotemporal white matter tracts
(Fig. 1). Although the mean w-maps for presymptomatic
carriers did not show any regions with low gray matter
(defined as w≤-2), we found that 20% of presymptomatic
carriers had low mesial temporal lobe volumes and low
white matter volume arose in approximately 10% (Fig. 1).
When calculating the difference between each partici-
pant’s mean left and right hemisphere w-score for gray or
white matter, we found that at individual level, both
symptomatic and presymptomatic participants had sym-
metric gray and white matter (maximum difference score
w = 0.78 for a symptomatic carrier).
We repeated these analyses with presymptomatic carri-
ers who had a CDR plus NACC FTLD score of 0 only.
Gray matter and white matter frequency w-maps showed
similar results (data not shown), supporting that the three
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presymptomatic carriers with CDR plus NACC FTLD
scores of 0.5 were not driving the overall results.
Mesial temporal lobe and relationships with
memory throughout the MAPT lifespan
To explore whether regions of low gray and white matter in
presymptomaticMAPT mutation carriers might worsen with
age, we created gray and white matter frequency w-maps for
each age decade represented within our data. We found that
approximately 20% of presymptomatic MAPT mutation car-
riers in their thirties showed low mesial temporal volumes
(Fig. 2). When examining carriers in their forties and fifties,
an increasing percentage of participants had low mesial tem-
poral gray matter with each additional decade. The white
matter frequency map (Fig. 1) suggested that low white mat-
ter volumes also arise in certain presymptomatic carriers,
but in contrast to the gray matter maps, the percentage of
participants with low white matter volumes did not clearly
increase with each decade.
For symptomatic carriers with CDR plus NACC
FTLD global scores of 0.5, mesial and anterior temporal
lobe and anterior cingulate atrophy were most common,
followed by insula and regions in dorsolateral prefrontal
cortex (Fig. 3). With worsening symptom severity, atro-
phy within these regions grew increasingly more common
and extensive. All carriers with a CDR plus NACC
FTLD global score of 1 had mesial temporal lobe atrophy
and all carriers with a global score of 2 had regions of
anterior cingulate and insular atrophy. By the time carri-
ers reached a global score of 3, all showed widespread
frontotemporal, insula, and uncinate fasciculus atrophy.
We examined relationships between memory measures
and the hippocampus, selected as an a priori region of
interest, and voxelwise gray matter maps. Verbal and spa-
tial memory z-scores were correlated with hippocampal
volumes across the whole MAPT cohort. Across symp-
tomatic and presymptomatic carriers combined, lower
scores in verbal recall (CVLT-II) were associated with
lower left hippocampal volume (rho = 0.70, P < 0.001)
and lower scores in visual recall were associated with
lower right hippocampal volume (rho = 0.44, P < 0.001).
To explore whether a MAPT-targeted gray matter region
is also associated with memory measures, we created a
Table 2. Neuropsychological testing of North American cohorts.
Test















MoCA, total score 28 [26, 29] 0.11 [0.96, 0.64] 22 [11, 25] 3.10 [8.97, 1.49] 11.24 (5, 79)1,2
Executive Functions/Processing Speed/Attention
Trails A, correct lines per minute 80.15 (24.58) 0.24 (0.94) 37.58 (20.11) 1.38 (0.77) 8.67 (5, 88)1,2
Trails B, correct lines per minute 34.42 (10.68) 0.33 (1.03) 16.65 (9.88) 1.39 (0.96) 8.00 (5, 88)1,2
Digit span forward 9.03 (2.31) 0.16 (0.98) 6.50 (2.85) 0.91 (1.21) 2.84 (5, 112)1,2
Digit span backward 8.00 (2.80) 0.21 (1.21) 5.24 (2.44) 0.99 (1.05) 3.45 (5, 113)1,2
Semantic fluency, animals in 1 min 24.21 (6.34) 0.08 (1.17) 12.12 (8.42) 2.14 (1.55) 12.79 (5, 113)1,2
Lexical fluency, words in 1 min 28.96 (7.04) 0.10 (0.91) 18.15 (12.73) 1.29 (1.64) 7.10 (5, 81)1,2
Memory4
Total recall (California Verbal Learning
Test, short form, four learning trials
total)
31 [29, 32.5] 0.23 [0.28, 0.61] 18 [15, 24] 3.09 [3.86, 1.56] 9.67 (5, 101)1,2
Delayed free recall (California Verbal
Learning Test, short form, 10 min
recall)
7 [6, 9] 0.35 [0.95, 0.85] 0 [0, 5] 4.54 [4.54, 1.54] 12.11 (5, 101)1,2
Benson figure 10 min recall, total score 14 [12, 16] 0.42 [0.48, 1.31] 10 [4, 12] 1.37 [4.05, 0.48] 6.45 (5, 114)1,2
Language4
Multilingual Naming Test, total score 29.5 [27, 31] 0.39 [1.67, 0.38] 26.5 [22.5, 28.5] 1.92 [3.97, 0.90] 7.56 (5, 80)1-3
Visuospatial4
Benson figure copy, total score 16 [15, 16] 0.09 [0.99, 0.09] 16 [15, 16] 0.09 [0.99, 0.09] 0.60 (5, 114)
Means and standard deviations (SD) or medians and interquartile ranges (IQR) are reported.
1Symptomatic cohort is significantly different from controls at P < 0.05.
2Presymptomatic cohort is significantly different from symptomatic cohort at P < 0.05.
3Presymptomatic cohort is significantly different from controls at P < 0.05.
4Z-scores estimated from reflected and log-transformed data were used to fit the regression models.
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spherical region of interest centered on a left hippocam-
pus voxel where carriers most frequently had low gray
matter. We also created its contralateral homolog. Lower
verbal recall scores were associated with lower volume
within this left hippocampal sphere (rho = 0.66,
P < 0.001), while lower scores in visual recall were







mean(SD) or median[IQR] F (df)
Global Cognition1
MMSE, total score 29.5 [29, 30] 0.28 [0.28, 0.85] 3.88 (4, 37)
Executive Functions/Processing Speed/Attention
Trails A, correct lines per minute 58.90 (21.66) 0.30 (1.08) 4.37 (4, 37)
Trails B, correct lines per minute 28.44 (11.99) 0.46 (1.29) 4.08 (4, 37)
Digit span forward 8.93 (2.56) 0.04 (1.32) 1.79 (4, 37)
Digit span backward 6.50 (1.74) 0.05 (0.89) 2.04 (4, 37)
Semantic fluency, animals in 1 min 26.93 (6.17) 0.52 (1.22) 1.94 (4, 37)
Lexical fluency, total D, A, and T words 36.57 (14.94) 0.25 (1.30) 0.72 (4, 37)
Memory
Total Recall (Rey Auditory Verbal Learning Test, total) 48.36 (8.95) 0.54 (0.96) 3.87 (4, 37)
Delayed Free Recall (Rey Auditory Verbal Learning Test) 9.79 (3.75) 0.34 (1.20) 2.34 (4, 37)
Language1
Boston Naming Test, total score 54.5 [50, 58] 0.07 [0.92, 0.85] 1.08 (4, 37)
Visuospatial1
Clock drawing 12.5 [12, 13] 0.05 [0.39, 0.29] 1.16 (4, 37)
Means and standard deviations (SD) or medians and interquartile ranges (IQR) are reported.
The Erasmus presymptomatic cohort did not differ from controls for any measure.
1Z-scores estimated from reflected and log-transformed data were used to fit the regression models.
Figure 1. Gray and white matter frequency w-maps grouped by clinical stage. Frequency w-maps show the percentage of subjects within the
group, ranging from 1% (magenta) to 100% of subjects (red), who have low gray or white matter volumes with w≤-2 in a given voxel. Top row,
left: All MAPT mutation carriers within the symptomatic group have anteromesial temporal atrophy. Top row, right: Symptomatic carriers have
atrophy in the uncinate fasciculi, corpus callosum, and anterior corona radiata. Bottom row, left: Approximately 20% of presymptomatic MAPT
mutation carriers show low gray matter volume in the mesial temporal lobes. Bottom row, right: Few carriers show low white matter volume
before symptom onset. All maps are shown on the Montreal Neurological Institute template brain with the left side of the axial and coronal slices
corresponding to the left side of the brain.
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associated with lower right hippocampal sphere volume
(rho = 0.50, <0.001). Voxelwise, lower verbal recall was
correlated with lower hippocampal volume bilaterally,
while lower visual recall was associated with lower volume
in a small clusters of the left hippocampus and other scat-
tered voxels (Fig. 4). These three analyses (whole hip-
pocampus, hippocampal sphere, voxelwise) were repeated
with symptomatic and presymptomatic carrier subgroups
and showed no statistically significant correlations
between memory measures and gray matter.
We repeated each of these analyses by excluding the
three presymptomatic carriers with the CDR plus
NACC FTLD score of 0.5 and results were unchanged.
Most MAPT mutation subtypes target
frontotemporal cortex
When mean w-maps were calculated for each MAPT sub-
type, we found that most of the symptomatic MAPT
mutation subtype groups (bvFTD-type, PSP/PD type, 4R-
type) shared a consistent pattern of fronto-insulo-
temporal atrophy (Fig. 5). Of those groups, the bvFTD-
type group showed the most severe gray and white matter
frontotemporal atrophy, while the PSP/PD type group
showed the most severe atrophy within the mesial tempo-
ral lobes (Fig. 5). One notable exception to the shared
frontotemporal atrophy pattern, however, was the R406W
mutation group, which typically results in an amnestic
presentation. R406W carriers lacked the frontal gray and
white matter atrophy that was characteristic of the other
MAPT mutation subtypes, and instead only showed bilat-
eral temporal and insular atrophy. Similar to the bvFTD-
type and 4R-type mutations, the PSP/PD group showed
frontotemporal atrophy, but additionally showed promi-
nent midbrain atrophy. The presymptomatic carriers with
PSP/PD-related mutations had low bilateral anterior cin-
gulate, insula and mesial temporal volumes and were also
the only presymptomatic group with voxels of low mid-
brain volume, albeit in sparse regions. We found no dif-
ferences in results when the three presymptomatic carriers
with a CDR plus NACC FTLD score of 0.5 were
excluded.
Figure 2. Gray and white matter frequency w-maps of presymptomatic carriers grouped by age decade. Gray matter (left) and white matter
(right) frequency w-maps for presymptomatic carriers divided by age decade (rows). Color bar indicates the percentage of subjects within each
age decade with low gray or white matter volumes of w≤-2 in a given voxel. Low mesial temporal lobe volumes arise in about 20% of MAPT
mutation carriers as early as their thirties. All maps are shown on the Montreal Neurological Institute template brain with the left side of the axial
and coronal slices corresponding to the left side of the brain.
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Discussion
In this study, we took a comprehensive approach to iden-
tify individual-level variation in gray and white matter vol-
ume and their relationships with age or symptom severity
across the MAPT continuum. We also identified relation-
ships between memory performance and gray matter to
explore whether specific MAPT mutation subtypes were
associated with distinct atrophy patterns. We found that
presymptomatic MAPT mutation carriers have low mesial
temporal volumes that are topographically similar to the
atrophy pattern seen in symptomatic carriers. Low mesial
temporal lobe volumes arose in about 20% of the presymp-
tomatic carriers during their thirties, and regions with low
gray matter appeared more common in presymptomatic
carriers with each increasing decade. Fewer than 10% of
presymptomatic carriers had low white matter values in
affected regions. For symptomatic carriers, mesial temporal
cortex was ubiquitously atrophied in carriers with a CDR
plus NACC FTLD global score of 1 or greater, with
widespread atrophy in frontotemporal cortex in those with
more advanced symptoms. In MAPT mutation carriers,
poorer memory performance was associated with lower
hippocampal volume. We found that atrophy in fron-
totemporal and insular cortex and the uncinate fasciculi,
inferior longitudinal fasciculi, and corpus callosum were
commonly observed across different MAPT mutations dur-
ing the symptomatic phase, with the exception of the
R406W mutation carriers who lacked the frontal atrophy
characteristic of otherMAPT mutation carriers.
A subset of presymptomatic carriers shows
low mesial temporal volumes
As in previous studies, we found that frontotemporal cor-
tex is targeted in symptomatic MAPT mutation carriers.2,3
Compared to patients with sporadic bvFTD and those
with other FTLD mutations, prominent mesial temporal
atrophy is more prevalent in MAPT mutation carri-
ers,2,35,36 who feature correspondingly greater memory
Figure 3. Gray and white matter frequency w-maps of symptomatic carriers grouped by symptom severity. Gray matter (left) and white matter
(right) frequency w-maps for symptomatic carriers binned by symptom severity, as defined by the CDR plus NACC FTLD global score (FTLD-
CDR). Color bar indicates the percentage of subjects within each symptom severity category with gray or white matter atrophy of w≤-2 in a given
voxel. Mesial temporal lobe atrophy becomes ubiquitous in those with an FTLD-CDR score of 1. With worsening severity, atrophy within temporal
and frontal lobes, insula and anterior cingulate are increasingly more common and extensive. All maps are shown on the Montreal Neurological
Institute template brain with the left side of the axial and coronal slices corresponding to the left side of the brain.
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impairment.23,37 Although mean group w-maps did not
identify regions of low matter in presymptomatic carriers,
frequency w-maps revealed that 20% of this group had
low mesial temporal volume. While early studies sug-
gested that gray matter abnormalities were undetectable
in presymptomatic MAPT mutation carriers,4,5 recent lar-
ger studies suggested that presymptomatic carriers have
low hippocampal and amygdalar volumes.6,8,17,38 Several
potential explanations may account for these varied
results. First, low gray matter volumes during the
presymptomatic phase are subtle and thus are likely to be
detectable only with larger cohorts. Second, previous
studies of presymptomatic carriers have performed group
analyses, which may be insensitive to low brain volumes
present in a minority of participants. By examining fre-
quency maps, we were able to identify the subset of carri-
ers with abnormally low gray and white matter volumes,
thus circumventing this limitation. Third, the presymp-
tomatic carriers in the present study and previous studies
could have differences in the number of years until actual
symptom onset. An individual’s age of onset and mean
familial age of onset are highly correlated, and perhaps
more strongly correlated for MAPT mutation carriers
compared to other FTLD mutations.6,39 Although the
mean age of the presymptomatic cohort in the present
study is similar to previous studies,5,8,39 age and mean
familial age of onset remain imperfect methods for esti-
mating the actual age of onset. Whether lower hippocam-
pal gray matter volumes portend earlier conversion to the
symptomatic phase remains an open question.
In contrast to sporadic bvFTD, memory impairment is
a feature of bvFTD due to MAPT mutations.40,41 Indeed,
we found that episodic memory, particularly verbal mem-
ory, was the most severely affected domain in symp-
tomatic carriers. Despite memory and language
impairments and lower than average executive perfor-
mance, visuoconstructional performance was similar to
controls. Our results showed that in all MAPT carriers
combined, poorer memory performance was correlated
with lower hippocampal volumes. Although hippocampal
atrophy has been reported in MAPT,2,3,6,8,17,36,38 to our
knowledge, previous studies have not directly correlated
memory performance with hippocampal volume in
MAPT mutation carriers. The hippocampus is well-estab-
lished for its importance in episodic memory19,20 and our
results support that this structure underlies the memory
impairment in MAPT. Our subgroup analyses of symp-
tomatic and presymptomatic carriers failed to identify sig-
nificant correlations between memory measures and
hippocampal volume. Smaller subgroup sample sizes,
floor effects in the symptomatic carriers’ memory scores,
and the limited dynamic range of presymptomatic carri-
ers’ memory scores serve as possible explanations for
these results.
Compared to gray matter, low white matter volume
arose less frequently among presymptomatic carriers.
One possibility is that gray matter decline precedes
white matter decline during the presymptomatic phase.
Consistent with this notion, a study of five presymp-
tomatic MAPT mutation carriers followed over four
years found that upon visual inspection, the extent of
gray matter loss appeared more pronounced than white
matter integrity loss.42 Although the present study
showed that low white matter volumes as assessed by
voxel-based morphometry were not prevalent in
presymptomatic MAPT, diffusion tensor imaging studies
have reported lower white matter tract integrity in
presymptomatic MAPT compared to controls.7,43 Voxel-
based morphometry may be less sensitive at detecting
white matter differences compared to diffusion tensor
imaging, thus future studies using multiple imaging
modalities are needed.
Regions of low gray and white matter may
reflect early neurodegeneration in
presymptomatic carriers
Certain presymptomatic carriers in their thirties showed
low mesial temporal volumes, consistent with a previous
Figure 4. Voxelwise correlations between memory measures and
gray matter. Maps show regions where verbal (top row) or spatial
(bottom row) memory z-scores were significantly correlated with
regions of low gray matter volume across all MAPT mutation carriers.
Lower scores on a verbal memory measure was associated with low
volume in bilateral hippocampi and inferior temporal regions. Lower
scores on a spatial memory measure was associated with low gray
matter in small scattered clusters including the left hippocampus,
right middle frontal gyrus, frontal pole, and left dorsal parietal lobe.
Maps were thresholded at P < 0.05, corrected for family-wise error.
Color bars show t-value ranges. All maps are shown on the Montreal
Neurological Institute template brain with the left side of the axial
and coronal slices corresponding to the left side of the brain.
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study suggesting that gray matter trajectories indicate low
hippocampal and amygdalar volumes arising 15 years
before estimated symptom onset.6 While regions with low
gray matter could in part reflect neurodevelopmental dif-
ferences as has been suggested for the C9orf72 repeat
expansion,44,45 our data indicate that presymptomatic car-
riers more frequently had low volumes within canonical
regions that are targeted in MAPT mutations with each
age decade. This finding suggests that a subset of
presymptomatic carriers may be undergoing incipient
neurodegeneration, with more carriers following suit as
symptom onset approaches. Interestingly, the frequency
of low mesial temporal lobe volumes appeared to outpace
other regions with increasing age, underscoring the
notion that the mesial temporal lobe is targeted early in
MAPT mutation carriers and becomes increasingly ubiq-
uitous with age and throughout the symptomatic phase.
A recent study of 14 presymptomatic MAPT mutation
carriers studied over a median of 9 years revealed that the
rate of temporal lobe gray matter decline outpaced the
rate of decline in the frontal and parietal cortices, suggest-
ing that low temporal gray matter volumes in presymp-
tomatic carriers may represent early neurodegeneration.46
Most MAPT mutation subtypes converge on
frontotemporal atrophy
Despite the different mechanisms of each mutation on
tau protein biology and neuropathology, patients with
different MAPT mutation subtypes converged on a highly
similar pattern of frontal and anterior, mesial and lateral
temporal atrophy with a corresponding predominance of
bvFTD diagnoses.15,47,48 Another study found that six
MAPT mutation subtypes shared anterior temporal gray
matter atrophy.41 IVS10 + 16, IVS10 + 3, N279K, and
S305N additionally showed mesial temporal atrophy,
while P301L and V337M had lateral temporal regions tar-
geted, with relative sparing of the mesial temporal lobe.41
In contrast, our V337M symptomatic carriers showed
mesial temporal involvement. Both the present study and
Figure 5. Atrophy patterns by MAPT mutation subtype —mean w-maps. Mean w-maps show the mean w-score in gray and white matter across
all subjects grouped by clinical stage. Rows reflect five different mutation subtype groupings. Frontotemporal atrophy patterns are similar across
mutation groups, except for the amnestic type R406W mutation group, which lacks frontal atrophy. Mutation subtypes associated with
progressive supranuclear palsy or parkinsonism distinctly show midbrain atrophy for both the symptomatic and presymptomatic groups. The
decade of the mean age for each group is indicated rather than the specific mean age in order to protect participant anonymity. Group maps are
thresholded from w≤-13 to 2. All maps are shown on the Montreal Neurological Institute template brain with the left side of the axial and
coronal slices corresponding to the left side of the brain. DD: disease duration.
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previous studies have investigated small numbers of par-
ticipants for each mutation subtype, such that clinical
heterogeneity may influence results.
Two notable exceptions arose when studying MAPT
mutation subtypes. R406W is the only knownMAPT muta-
tion that causes an amnestic syndrome rather than a behav-
ioral syndrome,22,23 and it typically causes mesial temporal
atrophy while sparing the frontal lobes relative to other
MAPT mutations.22,23,49,50 We found that R406W carriers
exclusively showed mesial and lateral temporal atrophy, but
lacked frontal atrophy, which may explain why these carriers
develop an amnestic rather than a bvFTD syndrome. Among
theMAPTmutations we studied, N279K, S305N, and S305S
cause PSP and parkinsonism. Interestingly, this group was
the only MAPT group which had midbrain atrophy, and
midbrain atrophy has been associated with patients with
PSP.51 An important caveat to our findings is that variability
in age and disease duration within the subtype groups may
be contributing to differences in atrophy because the partici-
pant numbers are limited for each group. Remarkably, the
average disease duration ranged from 2.7 ( 2.7) years for
the 4R-type mutation group to 19.5 ( 10.1) years for
V337M carriers, yet despite this wide range, the magnitude
of atrophy among the four mutation groups was similar.
This long disease duration and relatively old average age of
onset suggests that V337Mmight have a more indolent, pro-
tracted disease course compared to the other mutations.
Limitations
This study examined one of the largest MAPT cohorts to
date, but sample sizes were still small within most mutation
subtypes and larger cohorts are needed to study individual
MAPTmutations. To maximize power, we combined differ-
ent mutation subtypes based on clinical or neuropathologi-
cal similarity. Although we examined relationships of gray
and white matter with age, this study had a cross-sectional
design and longitudinal analyses are needed to map disease
trajectories. The extent to which focal regions with low gray
and white matter in presymptomatic mutation carriers may
be due to neurodevelopmental differences versus early neu-
rodegeneration remains unknown. Yet, the present study
and current literature support the notion that low gray and
white matter volumes in presymptomatic MAPT mutation
carriers represent early neurodegeneration. Longitudinal
studies will clarify these questions by mapping trajectories in
MAPT mutation carriers from early life through the symp-
tomatic phase.
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Figure S1. Gray and white matter mean w-maps of symp-
tomatic carriers. Maps show the mean w-score of gray
and white matter across the symptomatic carriers.
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Symptomatic carriers have atrophy in frontotemporal cor-
tex, insula, uncinate fasciculus, anterior corona radiata,
corpus callosum, and inferior longitudinal fasciculus.
Maps are thresholded from w≤-13 to 2. All maps are
shown on the Montreal Neurological Institute template
brain with the left side of the axial and coronal slices cor-
responding to the left side of the brain.
Table S1. Participants by Site
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